- 1、本文档共6页,可阅读全部内容。
- 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
P3 (无法标黄)Timing of New Black Box Warnings and Withdrawals for Prescription Medications
ORIGINAL CONTRIBUTION
Timing of New Black Box Warnings and
Withdrawals for Prescription Medications
Karen E. Lasser, MD, MPH Context Recently approved drugs may be more likely to have unrecognized ad-
Paul D. Allen, MD, MPH verse drug reactions (ADRs) than established drugs, but no recent studies have
examined how frequently postmarketing surveillance identifies important ADRs.
Steffie J. Woolhandler, MD, MPH
Objective To determine the frequency and timing of discovery of new ADRs de-
David U. Himmelstein, MD scribed in black box warnings or necessitating withdrawal of the drug from the market.
Sidney M. Wolfe, MD Design and Setting Examination of the Physicians’ Desk Reference for all new chemi-
David H. Bor, MD cal entities approved by the US Food and Drug Administration between 1975 and 1999,
and all drugs withdrawn from the market between 1975 and 2000 (with or without a
DVERSE DRUG REACTIONS prior black box warning).
(ADRs) are believed to be a Main Outcome Measures Frequency of and time to a new black box warning or
leading cause of death in the drug withdrawal.
AUnited States.1 Prior to ap- Results A total of 548 new chemical entities were approved in 1975-1999; 56 (10.2%)
proval, drugs are studied in selected acquired a new black box warning or were withdrawn. Forty-five drugs (8.2%) ac-
populations2,3 for limited periods
您可能关注的文档
- 克林霉素致味觉异常1例并文献分析_温晓娜.pdf
- 亚油酸通过调控胰岛素信号通路抑制胰岛素抵抗.pdf
- B130619_1708--PHMG降解谱图.pdf
- 马里、布基纳法索登记简介.pdf
- 印度制药业对美国通用名药物市场的影响.pdf
- 安徽省合肥地区医务人员对药品不良反应认知度和态度的研究.pdf
- 无菌液体药品的过程验证.pdf
- 48-基因治疗.pdf
- 尤瑞克林治疗急性前循环脑梗死的近期疗效和安全性研究.pdf
- 25家基层医疗卫生机构实施药品不良反应监测情况的调查分析_林宇_.pdf
- 《JJF 2132-2024荧光紫外灯人工气候老化试验装置校准规范:辐射照度参数》.pdf
- JJF 2120-2024轮速传感器校准规范.pdf
- 计量规程规范 JJF 2120-2024轮速传感器校准规范.pdf
- 《JJF 2129-2024钙钛矿太阳电池校准规范:光电性能参数》.pdf
- JJF 2129-2024钙钛矿太阳电池校准规范:光电性能参数.pdf
- 《JJF 2120-2024轮速传感器校准规范》.pdf
- JJF 2117-2024沥青混合料理论最大相对密度仪校准规范.pdf
- JJF 2116-2024特定蛋白分析仪校准规范.pdf
- 《JJF 2116-2024特定蛋白分析仪校准规范》.pdf
- 计量规程规范 JJF 2117-2024沥青混合料理论最大相对密度仪校准规范.pdf
文档评论(0)